BostonGene has won four awards in the Research & Development, Product Launches, and Innovation categories in the 2025 ...

In the HARMONY Alliance Study of European randomized clinical trials, researchers sought to determine if MRD could serve as an intermediate endpoint in intensively treated AML.

The American Society of Hematology/ASH 2025 meeting included AML results from AAML1831, MyeChild01, BIG-1, and PALG-AML1/2016 studies.

This study retrospectively analyzed ten pediatric patients with HOX-driven AML who received revumenib maintenance after HSCT at a single-center. The median age was 10 years (range: 1-18). 80% (8/10) ...

Challenging federal funding cuts, minimal residual disease, and a busy field of CAR T-cell candidates characterized this year ...

The SAVE regimen achieved an 86% ORR in newly diagnosed AML, with high MRD-negative rates, especially in NPM1 mutations or KMT2A rearrangements. Significant myelosuppression and infectious ...

CLN-049 monotherapy demonstrates promising efficacy, including multiple complete responses and encouraging response durability, in a heavily ...

MRD negativity post-chemotherapy strongly predicts improved overall survival in AML, with a significant reduction in mortality risk. The study suggests MRD could serve as an earlier surrogate endpoint ...

In a large analysis presented at ASH's annual meeting, researchers reported that patients' MRD status after intensive chemo can predict their survival.

TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed AML ...

Time to next treatment ranged from 0 months to 15.8 years, with a median of 2.3 years. Minimal residual disease (MRD)-guided retreatment with anti-CD20 antibodies effectively lowers MRD levels and ...